Summary

Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market Research Report Information by Diagnosis & Treatment {(Diagnosis [Microbiological Culture Test, Polymerase Chain Reaction, and Imaging Studies {Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasonography}], Treatment(Antibiotics, Antimicrobial Therapy, and Surgery)}, by End User (Hospitals, Ambulatory Surgery Centers, and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
Market Overview
Diagnosis and Treatment of Staphylococcus Aureus Infection in Orthopedic Implants In 2022, the market was estimated to be worth USD 2.31 billion. The staphylococcus aureus infection diagnosis and treatment for orthopedic implant market industry is anticipated to experience a compound annual growth rate (CAGR) of 4.89% during the forecast period, increasing from USD 2.40 billion in 2023 to USD 3.87 billion by 2032. The market is experiencing growth due to the increasing prevalence of fractures and the increasing number of orthopedic surgeries associated with implants.
The demand for the diagnosis and treatment of staphylococcus aureus infections in orthopedic implants is on the rise due to the growing number of orthopedic surgeries. For example, Cleveland Clinic (US) reported in July 2023 that approximately 800,000 knee replacements are performed annually in the States. Additionally, the American Association of Hip and Knee Surgeons has identified prosthetic joint infection (PJI) as a severe issue that arises following total hip arthroplasty (THA), particularly when other health conditions are present, which increases the risk. The proportion of infections associated with staphylococcus aureus increased from 26.3% in 2008–2009 to 40% between 2020 and 2021.

Market segment insights
The Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market segmentation is based on diagnosis and treatment. Diagnosis is further segmented into microbiological culture test, polymerase chain reaction, and imaging studies.
The Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market segmentation is based on the end user, which includes hospitals, ambulatory surgical centers, and other entities.

Regional Perspectives
The market is segmented into the United States, Europe, China, Middle East & North Africa, and the Rest of the World by region. In 2022, the staphylococcus aureus infection diagnosis and treatment for orthopedic implant market in North America held the largest market share. This is a result of the increased prevalence of staphylococcus aureus infection in orthopedic implants, the superior healthcare infrastructure, and the increase in the number of orthopedic surgeries in the North American region.
The staphylococcus aureus infection diagnosis and treatment for orthopedic implants market in Europe is the second-largest market share, owing to the country's favorable reimbursement policies and the geriatric population. Additionally, the most significant market share was attributed to Germany in the staphylococcus aureus infection diagnosis and treatment for orthopedic implant market. The UK is anticipated to be the fastest-growing market in the European region.
It is anticipated that the Asia-Pacific staphylococcus aureus infection diagnosis and treatment for orthopedic implant market will experience substantial growth from 2023 to 2032. This is a result of the accelerated population growth, government initiatives and investments, and collaboration among healthcare stakeholders in the region.
The Middle East, Africa, and Latin America comprise the Rest of the World. The staphylococcus aureus infection diagnosis and treatment for orthopedic implant market in the regions is expected to experience growth as a result of ongoing research and development initiatives that are committed to the development of innovative diagnostic technologies, therapeutics, and preventive strategies.

Major Players
Xellia Pharmaceuticals (Germany), Wellona Pharma (India), Schwitz Biotech (India), Merck KGaA (Germany), Thermo Fisher Scientific Inc (US), BioMérieux SA (France), Siemens healthineers AG (Germany), Beckman Coulter Inc (US), Hoffmann-La Roche Ltd (Switzerland), and Pfizer Inc (US) are among the key companies in the Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research DATA FLOW:
3.5.2 Primary Research: Number of Interviews conducted
3.5.3 Primary Research: Regional Coverage
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Technique
3.8 DATA MODELING
3.8.1 microeconomic factor analysis:
3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Growing number of Orthopedic surgeries associated with implants
4.2.2 Increasing incidence of fractures
4.3 RESTRAINTS
4.3.1 Stringent regulatory requirements and lengthy approval processes
4.4 OPPORTUNITY
4.4.1 Technological treatment for orthopedic associated staphylococcus aureus infection
4.4.2 Growing awareness of early diagnosis and the development of early diagnosis products
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 Threat of New Entrants
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 Threat of Substitutes
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET
5.3 QUALITATIVE OVERVIEW ON TREATMENT MANAGEMENT FOR STAPHYLOCOCCUS AUREUS BEFORE CULTURE AND ITS IMPACT ON HEALTHCARE COST
5.4 INDICATIVE SHARE (%) FOR IMPLANTS AFFECTED BY STAPHYLOCOCCUS AUREUS BY REGION, (2022)
5.5 TOTAL NUMBER OF JOINT REPLACEMENTS AND COMPLICATED FRACTURES REPAIRED WITH PLATES AND SCREWS
5.6 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED.
5.7 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED WITH STAPHYLOCOCCUS AUREUS (SA) INFECTION
5.8 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS REVISED SURGERIES ARE DONE BASED ON AN SA INFECTION
5.9 TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES AND TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES INFECTED WITH SA
6 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT
6.1 OVERVIEW
6.2 DIAGNOSIS
6.2.1 Microbiological Culture Test
6.2.2 Polymerase Chain Reaction
6.2.3 Imaging Studies
6.2.3.1 Computed Tomography (CT)
6.2.3.2 Magnetic Resonance Imaging (MRI)
6.2.3.3 Ultrasonography
6.3 TREATMENT
6.3.1 Antibiotics
6.3.2 Antimicrobial Therapy
6.3.3 Surgery
7 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER
7.1 OVERVIEW
7.2 HOSPITALS
7.3 AMBULATORY SURGERY CENTERS
7.4 OTHERS
8 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 us
8.2.2 canada
8.3 EUROPE
8.3.1 germany
8.3.2 France
8.3.3 UK
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 ASIA-PACIFIC
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 South Korea
8.4.5 australia
8.4.6 Rest of Asia-Pacific
8.5 REST OF THE WORLD
8.5.1 Middle East & Africa
8.5.2 Latin America
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS, 2022
9.3 COMPETITOR DASHBOARD
9.4 PUBLIC PLAYERS STOCK SUMMARY
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 Product approval
10 COMPANY PROFILES
10.1 XELLIA PHARMACEUTICALS
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIES
10.2 WELLONA PHARMA
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIES
10.3 SCHWITZ BIOTECH
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 MERCK KGAA
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 Products OFFERed
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 KEY STRATEGIES
10.5 THERMO FISHER SCIENTIFIC INC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 products OFFERed
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 Key Strategy
10.6 BIOMÉRIEUX SA
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 products OFFERed
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 Key Strategy
10.7 SIEMENS HEALTHINEERS AG
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 products OFFERed
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 Key Strategy
10.8 BECKMAN COULTER INC
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 F. HOFFMANN-LA ROCHE LTD
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 KEY STRATEGIES
10.10 PFIZER INC
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 productS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 SWOT ANALYSIS
10.10.6 KEY STRATEGIES
11 DATA CITATIONS